23:17 , Jan 17, 2019 |  BC Extra  |  Company News

Management tracks: eGenesis names Sekhri CEO

Xenotransplantation company eGenesis Inc. (Cambridge, Mass.) hired Paul Sekhri as president and CEO. He succeeds interim CEO Julie Sunderland, who will become a director. Sekhri was president and CEO of Lycera Corp. (Ann Arbor, Mich.)...
23:50 , Dec 7, 2018 |  BC Extra  |  Company News

Management tracks: MiMedx, Akorn, Mallinckrodt

Following a spate of resignations this summer, MiMedx Group Inc. (NASDAQ:MDXG) announced three executive promotions. SVP of Strategic Initiatives Mark Landy was promoted to EVP and chief strategy officer. VP of Medical Affairs David Mason...
22:48 , Mar 9, 2017 |  BC Innovations  |  Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
01:07 , Dec 10, 2016 |  BC Extra  |  Company News

Management tracks

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said Deborah Waterhouse will succeed Dominique Limet at CEO of Viiv Heathcare, its HIV-focused joint venture with Pfizer Inc. (NYSE:PFE) and Shionogi & Co. Ltd. (Tokyo:4507). Limet is to step down...
08:00 , Dec 14, 2015 |  BioCentury  |  Finance

From early to exit

A steady stream of M&A during lean years and IPOs when the biotech markets heated up persuaded LPs that Sofinnova Partners ' early stage investment strategy can generate exits regardless of market conditions. The VC...
02:11 , Dec 9, 2015 |  BC Extra  |  Financial News

Sofinnova Partners raises EUR 300M for Fund VIII

France's Sofinnova Partners closed its Sofinnova Capital VIII fund at EUR 300 million ($324.6 million), the maximum cap for the fund and above its initial target of EUR 250 million ($270.5 million). Sofinnova intends to...
02:25 , Nov 11, 2015 |  BC Extra  |  Company News

Management tracks

Tauopathy therapeutic developer Asceneuron S.A. (Lausanne, Switzerland) appointed Hans Schikan chairman. Schikan is chairman of Complix N.V. (Diepenbeek, Belgium) and InteRNA Technologies B.V. (Nijmegen, the Netherlands) and previously was CEO of Prosensa Holding N.V. ,...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Financial News

Asceneuron completes venture financing

Asceneuron S.A. , Lausanne, Switzerland   Business: Neurology   Date completed: 2015-09-29   Type: Venture financing   Raised: CHF30 million ($30.7 million)   Investors: Sofinnova Ventures; SR One; Kurma Partners; Johnson & Johnson Development Corp.;...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Asceneuron's clinical path

Investors pulled the trigger on a CHF30 million ($30.7 million) A round for preclinical neurology play Asceneuron S.A. last week thanks to a combination of in vivo proof-of-concept data and advances in neurological imaging technologies...
01:05 , Sep 30, 2015 |  BC Extra  |  Financial News

Asceneuron raises CHF30 million series A round

Neurology company Asceneuron S.A. (Lausanne, Switzerland) raised CHF30 million ($30.7 million) in a series A round led by new investor Sofinnova Partners. Also participating were new investors SR One; Kurma Partners; and Johnson & Johnson...